Align Technology, Inc. (NASDAQ:ALGN) Receives $198.08 Consensus Target Price from Brokerages

Align Technology, Inc. (NASDAQ:ALGN) has been assigned a consensus rating of “Moderate Buy” from the fourteen research firms that are presently covering the stock, MarketBeat reports. Seven analysts have rated the stock with a hold recommendation and seven have given a buy recommendation to the company. The average 12 month target price among brokers that have issued ratings on the stock in the last year is $198.0833.

A number of research analysts have recently issued reports on ALGN shares. Jefferies Financial Group lifted their price objective on shares of Align Technology from $155.00 to $185.00 and gave the stock a “hold” rating in a research report on Thursday, February 5th. Mizuho increased their target price on shares of Align Technology from $200.00 to $215.00 and gave the company an “outperform” rating in a research report on Thursday, February 5th. UBS Group raised their target price on shares of Align Technology from $175.00 to $185.00 and gave the company a “neutral” rating in a research note on Thursday, February 5th. Morgan Stanley lifted their price target on shares of Align Technology from $154.00 to $169.00 and gave the stock an “equal weight” rating in a report on Thursday, February 5th. Finally, Stifel Nicolaus upped their price target on Align Technology from $200.00 to $210.00 and gave the stock a “buy” rating in a research report on Thursday, February 5th.

Trending Headlines about Align Technology

Here are the key news stories impacting Align Technology this week:

• Positive Sentiment: Elliott Investment Management has built a significant, reportedly “major” stake in Align, signalling potential engagement to push for actions that could boost shareholder value (strategic review, cost moves, buybacks or governance changes). This is the primary catalyst behind recent intraday upside. Elliott builds stake in Invisalign maker Align Technology – Reuters
• Positive Sentiment: Market coverage notes and press reports (Bloomberg/Yahoo) echo the stake build and include an updated company response — the combination of activist pressure plus public attention is often perceived as positive for near-term shareholder returns. Market Chatter: Activist Elliott Investment Builds Stake in Align Technology – Yahoo
• Positive Sentiment: Analyst/market reaction: ALGN saw premarket and intraday spikes on the reports and a recent upgrade to Overweight at Barclays, which may lend support to the stock if analysts follow with higher targets. Align Technology Raised to Overweight at Barclays – American Banking News
• Neutral Sentiment: Short interest posts in the data feed show zero shares (and 0 days to cover), which appears to be a reporting anomaly rather than a market signal — treat short-interest headlines with caution until clean data is published.
• Negative Sentiment: Structural headwinds remain: ALGN is still materially below its 2021 peak as dental/demand trends have normalized after the pandemic-era boom. Activist involvement can be positive but may also lead to strategic changes that create uncertainty or execution risk in the near term. Elliott Builds Major Align Stake as Shares Sit Near $172 – Yahoo

Insiders Place Their Bets

In related news, EVP John Morici sold 7,969 shares of the company’s stock in a transaction dated Wednesday, February 18th. The stock was sold at an average price of $189.31, for a total transaction of $1,508,611.39. Following the transaction, the executive vice president directly owned 8,237 shares of the company’s stock, valued at $1,559,346.47. This represents a 49.17% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link. 0.66% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Align Technology

A number of large investors have recently modified their holdings of ALGN. Vanguard Group Inc. grew its position in Align Technology by 0.7% during the 3rd quarter. Vanguard Group Inc. now owns 8,301,611 shares of the medical equipment provider’s stock worth $1,039,528,000 after purchasing an additional 58,546 shares during the last quarter. Capital International Investors raised its holdings in shares of Align Technology by 52.2% in the fourth quarter. Capital International Investors now owns 4,643,221 shares of the medical equipment provider’s stock worth $725,039,000 after buying an additional 1,592,848 shares during the last quarter. Ninety One UK Ltd lifted its stake in shares of Align Technology by 18.3% during the third quarter. Ninety One UK Ltd now owns 2,267,192 shares of the medical equipment provider’s stock worth $283,898,000 after buying an additional 350,883 shares during the period. Invesco Ltd. lifted its stake in shares of Align Technology by 37.4% during the third quarter. Invesco Ltd. now owns 1,497,535 shares of the medical equipment provider’s stock worth $187,521,000 after buying an additional 407,559 shares during the period. Finally, Capital World Investors grew its holdings in shares of Align Technology by 13.2% during the fourth quarter. Capital World Investors now owns 1,490,503 shares of the medical equipment provider’s stock valued at $232,742,000 after buying an additional 173,641 shares during the last quarter. Hedge funds and other institutional investors own 88.43% of the company’s stock.

Align Technology Trading Down 1.7%

ALGN opened at $173.18 on Friday. The firm has a market cap of $12.34 billion, a price-to-earnings ratio of 30.60, a PEG ratio of 1.89 and a beta of 1.79. Align Technology has a 12 month low of $122.00 and a 12 month high of $208.30. The stock has a fifty day moving average price of $176.55 and a 200-day moving average price of $154.55.

Align Technology (NASDAQ:ALGN) last issued its quarterly earnings data on Wednesday, February 4th. The medical equipment provider reported $3.29 earnings per share for the quarter, beating analysts’ consensus estimates of $2.99 by $0.30. The company had revenue of $1.05 billion for the quarter, compared to the consensus estimate of $1.03 billion. Align Technology had a return on equity of 15.16% and a net margin of 10.17%.The firm’s revenue for the quarter was up 5.3% compared to the same quarter last year. During the same quarter last year, the company earned $2.44 earnings per share. On average, equities research analysts forecast that Align Technology will post 7.98 EPS for the current year.

Align Technology Company Profile

Align Technology, Inc (NASDAQ: ALGN) pioneered the use of digital technology in orthodontics through the development of the Invisalign system, a series of clear, removable aligners that provide an alternative to traditional metal braces. Since its founding in 1997 by Zia Chishti and Kelsey Wirth, the Tempe, Arizona–based company has expanded its focus to include intraoral scanners, CAD/CAM software for dental laboratories and comprehensive digital dentistry solutions.

The company’s signature Invisalign system leverages 3D imaging and computer-aided design (CAD) to create customized aligners that gradually reposition teeth, improving patient comfort and treatment predictability.